Live
- Chanchalguda Jail Officials Say They Haven't Received Bail Papers Yet, Allu Arjun May Stay in Jail Tonight
- BJP leaders present evidence of illegal voters in Delhi, urge EC for swift action
- Exams will not be cancelled: BPSC chairman
- Nagesh Trophy: Karnataka, T.N win in Group A; Bihar, Rajasthan triumph in Group B
- YS Jagan condemns the arrest of Allu Arjun
- Economic and digital corridors to maritime connectivity, India and Italy building vision for future, says Italian Ambassador
- SMAT 2024: Patidar's heroics guide Madhya Pradesh to final after 13 years
- CCPA issues notices to 17 entities for violating direct selling rules
- Mamata expresses satisfaction over speedy conviction in minor girl rape-murder case
- Transparent Survey Process for Indiramma Housing Scheme Directed by District Collector
Decision on Covaxin in October, says WHO
World Health Organisation
A decision on Bharat Biotech's submission seeking emergency use listing (EUL) for its Covaxin Covid-19 vaccine will be made in October, the World Health Organisation has said.
United Nations/ Geneva: A decision on Bharat Biotech's submission seeking emergency use listing (EUL) for its Covaxin Covid-19 vaccine will be made in October, the World Health Organisation has said.
The status of assessment for Covaxin is "ongoing". Bharat Biotech had submitted EOI (Expression of Interest) on April 19 for its vaccine.
The latest 'Status of Covid-19 vaccines within WHO EUL/PQ evaluation process' guidance document dated September 29 on the WHO website said that the decision date for Bharat Biotech's Covaxin is "October 2021".
The WHO said it began rolling data of the vaccine on July 6. Rolling data allows the WHO to start its review right away, as information continues to come in, to accelerate the overall review process.
According to the WHO, submissions for prequalification or listing under the emergency use procedure are confidential. If a product submitted for assessment is found to meet the criteria for listing, the WHO will publish the results widely.
Duration of the emergency use listing process depends on the quality of the data submitted by the vaccine manufacturer and on those data meeting WHO criteria, according to the agency.
